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Background: An interesting ﬁnding in the epidemiology of human immunodeﬁciency virus 
(HIV) infection is that certain mutations in genes coding for chemokines, and their receptors 
and ligands, may confer resistance or susceptibility to HIV-1 infection and acquired immu-
nodeﬁciency syndrome (AIDS) progression. The mutation most frequently studied is stromal 
cell-derived factor (SDF)1-3′A, a single nucleotide polymorphism in the 3′ untranslated region 
at the 801 position of the SDF1 gene, which seems to be associated with susceptibility or resis-
tance to diseases, including AIDS. We examined the frequency of the above polymorphisms 
in the Tunisian population, and evaluated their contribution to a protective genetic background 
against HIV infection and progression.
Methods and materials: One hundred forty blood samples from HIV-infected patients 
from the Cellular Immunology Research Laboratory at the National Blood Transfusion Center 
were compared with those of 164 random blood donors from the same center. Genotyping was 
initially performed by polymerase chain reaction (PCR) analysis. SDF1 PCR product genomic 
regions were further subjected to restriction fragment length polymorphism analysis for 
genotype determination. Screening for the SDF1 polymorphism in the HIV-infected population 
yielded 56 heterozygous (40%), 52 mutation homozygous (37.1%), and 32 wild-type homozy-
gous (22.8%) subjects. In contrast, in our healthy population, we found 70/164 heterozygous 
(42.6%), nine mutation homozygous (5.4%), and 85 wild-type homozygous (51.8%) subjects. 
The allele frequencies in the HIV-infected and healthy populations were f(SD1 3′A) = 57.1%, 
f(SDF1) = 42.8%, f(SDF1 3′A) = 26.8%, and f(SDF1) = 73.1%, respectively. The allelic and 
genotypic frequencies of the SDF1 3′A in our population show signiﬁcantly higher distribu-
tion proﬁles compared with those observed in other Caucasian, European, and African American 
populations. Our results were examined by χ2 test and appear to conﬁrm an association between 
polymorphism and AIDS progression. A higher odds ratio (.1) was found for the SDF1-3′A 
allele than for the wild-type allele (,1).
Conclusion: This result seems to conﬁrm that the SDF1-3′A allele is associated with accelera-
tion and progression from HIV infection to AIDS in the Tunisian population.
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Introduction
The discovery that chemokines can block human immunodeﬁciency virus (HIV) rep-
lication, and that their receptors play an important role in fusion of HIV to target cells, 
has led to the expectation that chemokines might hold the key to understanding the 
pathogenesis of HIV . In fact, the chemokine receptors, together with the CD4 molecule, 
serve as necessary cofactors for HIV entry into CD4 cells.1 The chemokine ligand 
12 (CXCL12), better known as stromal cell-derived factor 1 (SDF1), inhibits infection of 
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T cell line-tropic or syncytium-inducing viruses, usually found 
during late-stage HIV infection. Two chemokine   receptors, 
CXCR4 and CCR5, are the major coreceptors required for 
entry of T cell line-tropic and macrophage-tropic strains of 
HIV-1, respectively, into CD4 cells.2,3 In addition, the expres-
sion of the SDF1 mutation, a single nucleotide polymorphism 
(designated SDF1-3′UTR-801G-A) at position 801 in the 
3′-untranslated region (UTR) of the SDF1 gene, the only 
known ligand of CXCR4,4 may inhibit transmission of T cell 
line-tropic HIV strains, and may be implicated in mechanisms 
of resistance to acquired immunodeﬁciency syndrome (AIDS) 
progression throughout the disease stages.5–7 However, other 
studies have not observed any progression-retarding effect, 
and have reported its association with a faster decline in CD4+ 
T cells and progression to AIDS.8,9
This mutation has been widely studied during recent years 
in many populations, as well as worldwide, but this study 
is the ﬁrst relevant research done in Tunisia. The global, 
ethnic, and regional distribution of these HIV/AIDS muta-
tions varies signiﬁcantly, giving each population a different 
genetic proﬁle for HIV infection and AIDS progression. In 
the present study, we investigated the frequency of SDF1-3′A 
polymorphism in the Tunisian population and compared its 
distribution with that in other populations. It must be noted 
that the odds ratio (OR) was estimated for our population in 
order to evaluate natural resistance, and, therefore, these indi-
ces are of special importance for the prevention of AIDS.
Materials and methods
Sample collection
This study was conducted in 2003–2008 in 1047 Tunisian 
patients with HIV disease on antiretroviral therapy who made 
visits to the Laboratory of Cellular Immunology in order 
to have their CD3, CD4, and CD8 immune cell numbers 
monitored by flow cytometry.
The patients comprised 727 (69.43%) men of median age 
37 years and 320 (30.56%) women of median age 34 years. 
These patients were sent to our laboratory by the Infectious 
Diseases Services of many hospitals, ie, La Rabta, Bourguiba, 
F Hached, A Othmana, as well as some private institutions. 
All information collected from this group of patients enabled 
us to follow the chronologic evolution of the disease in order 
to correlate it with numbers of CD4 immune cell lines in 
different stages of infection. HIV blood samples were also 
collected from 140 prospective patients, including 93 men of 
median age 36 years and 47 women of median age 34 years, 
in order to study the SDF1 polymorphism compared with 
that in 164 healthy donors.
Isolation of genomic DnA  
and genotyping
Five milliliters of blood was collected in an ethylenedi-
amine tetraacetic acid tube (15%), and DNA was extracted 
by a chemical method using TKM solution.10 SDF1 has 
three splice variants, among which the beta variant may 
have a guanine to adenine (G-A) mutation. Genotyping 
of the SDF1 3′A mutation was performed by polymerase 
chain reaction (PCR) using pairs of external primers (SDF1 
F 5′-CAGTCAACCTGGGCAAAGCC-3′ and SDF1 – R 
5′-AGGTTTGGTCCTGAGAGTCC-3′) framing the region 
surrounding the polymorphic sites, and restriction frag-
ment length polymorphism (RFLP) was done by using 
a restriction enzyme “MspI”. The SDF1 3′A variant was 
detected by electrophoresis on 1.5% agarose gel. Ethidium 
bromide staining was used to reveal the fragment under 
ultraviolet light. PCR products showed a band at base   
pair 302.11
If the 3′A allele existed at position 801, no digestion 
occurred and only one 302 base pair band in the agarose gel 
emerged, whereas if the wild-type allele (G) existed at this 
site, two shorter fragments, including a 200 and 100 base 
pair resulted.11
Statistical analysis
Allelic and genotypic frequencies were evaluated by tools 
used for population genetic analyses, ie, SPSS version 16.0 
(SPSS Inc., Chicago, IL), as well as by calculating OR and 
P values. In fact, we had to do an association study between 
SDF1 mutation and disease progression in order to identify 
genes or alleles associated with susceptibility or resistance to 
HIV   infection. The gene may be a risk factor for infection, if 
among the gene   expressions (alleles) one increases the risk 
of disease rather than having a protector effect. The χ2 test 
enables calculation of the P value, which is the probability 
of a different allelic distribution observed between the two 
groups occurring at random. The association was considered 
signiﬁcant for P , 0.05. The OR values can be .1. if 
OR . 1: accelerator allele; if OR, 1: protector allele, and 
if OR = 1: neutral allele.
Results
general representation of Tunisian 
patients living with HIV
In order to survey the influence of antiretroviral treatment 
on the dynamic rate of CD4 cells, blood samples from HIV 
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analysis. In total, 1047 patients were analyzed, with 
a 2:27 gender ratio. Our study was conducted during the 
period 2003–2008. Table 1 represents the distribution of 
the total number of patients, and their gender ratio and 
median age, which enabled study of the new HIV patient 
rate shown in Table 2.
SDF1 polymorphism study
The mixture of the PCR product and “MspI” restriction 
enzyme was stored at 37°C for one night. The restric-
tion enzyme cut in the 801 position in the 3′ UTR of the 
SDF1 gene. The digestion products were analyzed by 1.5% 
agarose gel electrophoresis and visualized by ultraviolet fluo-
rescence after staining with ethidium bromide. SDF1 wild-
type alleles (SDF1/SDF1 or G/G) yielded 100 and 200 base 
pair products, whereas mutation allele homozygotes (SDF1 
3′A/SDF1 3′A or A/A) and heterozygotes (SDF1 3′A/SDF1 
or A/G) yielded, respectively, 302 base pairs and 302, 200, 
and 100 base pair products.12 A 100 base pair molecular ruler 
was used as a marker. Figure 1 displays the PCR product, and 
Figures 2 and 3 show all the possible genotypes involving 
PCR and digestion products.
SDF1 3′A in HIV patients versus  
healthy donors
Patient genotypes were identiﬁed using   electrophoresis pro-
ﬁles. We counted 52 of 140 patients who were homozygous 
(37.1%), 56 who were heterozygous (40%), and 32 who were 
homozygous for the wild-type allele (22.8%). However, 
in the donor population, we counted only 9/164 patients 
who were homozygous for the mutation (5.48%), 70 who 
were heterozygous (42.6%), and 85 who were wild-type 
homozygous (51.8%). Table 3   summarizes the genotypic 
frequency in the healthy and infected populations, as well 
as the X2 test and P value, and Table 4 illustrates the allelic 
frequencies.
Table 4 demonstrates that the SDF1 3′A allele frequency 
is higher in the HIV population (57.1%) compared with the 
healthy donors (42.8%) in contrast with the wild-type allele 
which is more frequent in the healthy population (73.1%), 
and low in the HIV patient cohort (26.8%). This ﬁnding was 
highly signiﬁcant (P , 0.05) according to the χ2 test. This 
table also summarizes the allelic and genotypic frequencies 
of the SDF1 wild-type allele and SDF1 3′A alleles reported 
in different countries compared with the Tunisian cohort.
Polymorphism distribution according  
to clinical stage of infection
Three different stages were observed in disease progression 
of HIV infection, ie, clinical stages A (primo infection), 
B (intermediate), and C (ﬁnal). In the 140 infected patients, we 
counted 24 in clinical stage A, 25 in clinical stage B, and 70 in 
stage C. SDF1 3′A distribution was also carried out as a func-
tion of the clinical stages. Table 5 summarizes the results. The 
distribution study of SDF1 3′A in the initial stages shows nine 
homozygous for the mutated allele (A/A), nine heterozygous 
(A/G), and six homozygous for the wild-type allele (G/G). 
In the intermediate stage, we counted eight homozygous for 
the mutation, 12 heterozygous, and ﬁve homozygous for the 
wild-type allele. In contrast, for the ﬁnal stage, 30 patients 
homozygous for the mutation were detected, with 26 heterozy-
gous and 14 homozygous for the wild-type allele.
SDF1 polymorphism distribution by 
clinical stage and CD4+ T cell number
The relationship between SDF1 polymorphism, immune 
cell numbers, and clinical stage progression is shown in 
Figure 4.
Table 1 Age and gender distribution of patients with human 
immunodeficiency virus
2003 2004 2005 2006 2007 2008
Median age (years) 34.76 35.7 36.26 37.09 43.71 35.81
Men (n) 153 184 213 177 275 302
Women (n) 76 74 91 142 114 183
Total patients 229 258 304 319 389 485
Table 2 Rate of increase in numbers of patients with new human 
immunodeficiency virus in the Tunisian population
2005 2006 2007 2008
Women (n) 25 28 67 85
Men (n) 70 98 129 170
Total new patients 96 118 196 256
Rate increase (%) 18.51% 22.91% 66.1% 30.61%
302bp
200bp 
100bp 
Figure 1 Polymerase chain reaction product: The primers produce polymerase 
chain reaction products of either 302 base pairs.HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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Discussion
This is the ﬁrst study undertaken to determine the different 
aspects of the Tunisian HIV-infected population and the fre-
quency of the SDF1 3′A allele in a large sample of symptom-
atic HIV-infected subjects compared with healthy donors.
Analysis of the clinical, therapeutic, and biologic data for 
2003–2008 demonstrates many features peculiar to the Tuni-
sian cohort. For each year, we determined the median age of 
our patients, which shows a range between 34 and 43 years, 
giving a total median age of 37 years. This   observation 
  suggests that the HIV-infected Tunisian population is young 
compared with other cohorts12 and also shows that the prin-
cipal cause of disease transmission could be unprotected 
sexual activity. It is also important to note the large difference 
between the numbers of male and female HIV patients, with a 
gender ratio of 2:27. The rate of new cases in our population 
is increasing year by year, from 18.51% in 2005, to 22.91% 
in 2006, to 66.1% in 2007, and to 30.61% in 2008.
In the second part of this study, we tried to determine 
the role of SDF1 polymorphism in HIV infection and the 
role of the SDF1 3′A allele in delay or susceptibility to HIV 
  progression. The reported frequency of the homozygous gen-
otype for the SDF1 3′A allele observed in the HIV-infected 
population is 37.1% and only 5.4% in the healthy population. 
In addition, our study also demonstrates that, compared with 
the homozygous wild-type SDF1 allele, there is a frequency 
of 22.8% in the HIV-infected population and 51.8% in the 
healthy one. These results are comparable with those of a 
previous study in the Caucasian population,13 in Oceania, and 
in Asia.14 Moreover, analysis of the genotype frequency data 
conﬁrmed that our results are highly signiﬁcant (P # 0.05). 
Consequently, an association probably exists between HIV 
infection and SDF1 polymorphism.
No significant difference in the frequency of the 
heterozygous genotype between the HIV-infected population 
(40%) and healthy donors (42.6%) has been reported. 
Another particularity of the Tunisian population is that the 
SDF1 3′A allele frequency differed signiﬁcantly between 
our HIV-infected patients (57.1%) and our donor group 
(42.8%), whereas the wild-type allele of SDF1 is more 
frequent in the donor population (73.1%) than in the HIV-
infected   population (26.8%). This result is comparable with 
that in a previous study in a Caucasian population,13 and 
in Asia,14 Japan,15 and Greece.16 The contrast is observed 
in Italy17,18 and in the African American population.13 The 
χ2 test conﬁrms that our results are highly signiﬁcant 
(P # 0.05), so the SDF1 3′A mutation could be associated 
with progression or delay of HIV disease. For this reason, 
we investigated SDF1 polymorphism according to clinical 
stage of infection. The results showed that many of the 140 
HIV-infected patients were in the ﬁnal stages of infection 
(70/140); in contrast, there were 24 in clinical stage A and 
25 in clinical stage B.
300bp
200bp 
100bp
Figure  3  Polymerase  chain  reaction  restriction  fragment  length  polymorphism 
analysis  results  of  SDF1  followed  by  enzymatic  digestion  on  1.5%  agarose  gel 
(genotype observed, g/g).
Table 3 The frequency of different SDF1 genotypes, χ2 test, and 
P value
Genotypes HIV patients Donors P value
n Frequency n Frequency
SDF1 3′A/SDF1  
3′A (A/A)
52 0.371 (37.1%) 9 0.054 (5.4%) ,0.05
SDF1 3′A/SDF1  
(A/g)
56 0.40 (40%) 70 0.426 (42.6%) .0.05
SDF1/SDF1 (g/g) 32 0.228 (22.8%) 85 0.518 (51.8%) ,0.05
Abbreviation: HIV, human immunodeficiency virus.
Table 4 Allelic frequency distribution, χ2 test, P value and odds 
ratio (OR)
Allelic frequencies  HIV patients Donors P value OR
F (SDF1 3′A) or f(A) 0,571 (57,1%) 0,428 
(42,8%)
P < 0,05 >1
F (SDF1) or f(g) 0,268 (26,8%) 0,731 
(73,1%)
P < 0,05 <1
Abbreviation: HIV, human immunodeficiency virus.
AA 
300bp 
100bp
200b
Figure  2  Polymerase  chain  reaction  restriction  fragment  length  polymorphism 
results of SDF1 followed by enzymatic digestion on 1.5% agarose gel (genotypes 
observed, A/A and A/g).HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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In addition, the homozygous mutation for the SDF1 
3′A allele differs among patients in various stages of HIV 
infection, and most of the patients in the ﬁnal stage are 
homozygous for the mutated allele 3′A (30/70) which seems 
to be the most frequent, and is pronounced every time upon 
progression to the later stage of infection.13,16,19–21 This result 
is in agreement with other studies conﬁrming that SDF1-3′A 
homozygosity is associated with a faster CD4 T cell decrease 
and a rapid progression to AIDS.8.22,26 However, different 
investigations conﬁrm that, in contrast, SDF1 3′A/SDF1 
3′A has a protective effect, and there was a marked slowing 
in progression to AIDS. Furthermore, the gradation suggests 
that the protection afforded by the mutation is more marked 
in the later stages of HIV infection, and is possibly related 
to inhibition of T cell-tropic HIV strains.13
Finally, we used a cross-sectional approach to analyze 
for the presence of SDF13′A, and correlated it with clinical 
stage and number of CD4+ T cells. The results show that most 
patients in the ﬁnal stages of infection carry the mutated 
allele, which is present when the CD4+ T cells decrease 
below 200/mm3 (the CD4+ threshold). Furthermore, the χ2 
test shows that the SDF1 3′A OR is .1, which suggests 
that, in our population, the 3′A allele may accelerate to 
the ﬁnal stage of infection, in contrast with the wild-type 
allele (SDF1) which seems to be protective (OR , 1). This 
result is in agreement with another study carried out in the 
Sub-Saharan African population which conﬁrmed that the 
mutation was associated with an increased risk for HIV 
infection.23
In molecular terms, many studies conﬁrm that the SDF-1 
3′A mutation leads to increased levels of SDF1 mRNA, 
and demonstrate also that this effect is a consequence of 
enhanced mRNA stability.29 This observation is supported 
by other studies showing that homozygosity is associated 
with delayed progression to AIDS, and, because the 3′ UTR 
is also involved in regulating the stability of mRNA, it has 
been suggested that this homozygosity might involve over-
production of SDF1 that could act by inhibiting the appear-
ance of X4 strains and by competing with the HIV-1 virulent 
X4 and R5X4 strains for binding to the CXCR4 coreceptor 
of the target cells.13,30
In our study we identiﬁed a correlation between SDF1 
genotyping results and progression of the clinical stages of 
HIV infection in the Tunisian population according to the 
number of CD4+ T cells. We found an association between the 
presence of the SDF1 3′A allele and risk of HIV in a Tunisian 
cohort, and observed a statistically signiﬁcant difference 
Table 5 Allelic and genotypic frequencies of SDF1, wild-type allele, and SDF1 3′A reported in different countries compared with the 
Tunisian cohort 
Countries  HIV patients  n Controls  n References
Allelic frequencies (%) SDF1 3′A SDF1 SDF1 3′A SDF1
Japan 34.47 – 393 – – – Ikegawa et al15
Poland 14.6 – 1063 – – – Lewandowska et al24
Italy 15.0 – 37 – – – Su et al18
Pavia  3.6 – 55 – – – guerini et al17
Southern Spain 24.5 – 100 – – – Royo et al25
Spain  32.32 67.68 164 8.33 91.67 60 Soriano et al26
Russia  22.2 – 171 – – – Ryabov et al27
greece 29.75 – 200 – – – Apostolakis et al16
South India 17–35 – 525 – – – Ramana et al
north India 20.4 – 500 – – – Verma et al21
Caucasian 21.1 – 1835 – – – Winkler et al13
African Americans 5.7 – 859 – – –
Asian 25.7 – 37 – – –
Brazilian Caucasians 18.84–23 – 469 – – – eMV Reiche et al (2006)
Brazilian non-Caucasians 14–20 – 225 – – –
Asia (Oceanian) 50–70 – – – – – Arezana-Seisdedos et al14
Tunisia 57.1 42.8 140 26.8 73.1 164 Present study
Abbreviations: n, total number; (-), data not available; HIV, human immunodeficiency virus.
Table 6 SDF1 polymorphism distribution according to clinical 
stages
Genotypes Clinical stages
A B C
A/A 9 8 30
A/g 9 12 26
g/g 6 5 14
Total 24 25 70HIV/AIDS - Research and Palliative Care 2010:2 submit your manuscript | www.dovepress.com
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in genotype and allele frequencies between patients and 
a healthy control group. There were significantly more 
patients than healthy individuals who were homozygous for 
SDF1 3′A. The progression-delaying effect of the SDF1 3′A 
genotype was not conﬁrmed in our population, but we did 
demonstrate signiﬁcant expression of the 3′A allele in the 
later stages of infection, that may be related to the evolution 
of HIV infection and suggests an accelerator role of this allele 
for progression to AIDS. In fact, most of our AIDS patients 
carry the 3′A mutation, with an important decrease in CD4 
immune cells in the late stage of disease. This may be related 
to overproduction of chemokines and immune cells which 
exhausts the already deﬁcient immune system, causing a 
faster decline in CD4+ T cells and progression to later stages 
of disease. This impression should be conﬁrmed by further 
molecular studies, as well as quantiﬁcation of viral charge and 
plasma SDF1 levels in order to perform a molecular analysis. 
It would be most important to include other researchers’ 
results in association with SDF1 polymorphism based on 
the roles of further chemokines, and their receptors and 
interactions in HIV infection and AIDS progression.
Conclusion
This study highlights the clinic, epidemiologic, and biologic 
characteristics of HIV patients in a Tunisian population, 
identiﬁes genetic polymorphism of SDF1, and compares 
them with a healthy control population. Our results show the 
accelerative effect of the SDF-1 3′A allele to the late stage 
of infection and disease progression, in contrast with the 
wild-type allele, which seems to be protective. No progres-
sion-delaying effects have been detected for this mutation 
in our population, but it is associated with a faster decline 
in CD4+ T cells and progression to AIDS.
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